Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9fludarabine 8Cytarabine 8Busulfan 8Azacitidine 8Whole-Body Irradiation 7Methotrexate 7Cyclosporine 6Tacrolimus 5Filgrastim 5Decitabine 5nilotinib 4Mycophenolic Acid 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Dasatinib 3Biopsy 3AP 1903 reagent 3venetoclax 2sabatolimab 2ruxolitinib 2merphos 2magrolimab 2ivosidenib 2decitabine and cedazuridine drug combination 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × sabatolimab × Myeloid × Clear all
NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Novartis

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04283526 2021-03-04

Study of Select Combinations in Adults With Myelofibrosis

Novartis

Phase 1 Withdrawn
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡